Research Synthesis: Rapamycin Biomarker Effects — full paper

Researka accepted publication: b3041d87-87dd-46e9-a8ea-5a13c317c885 Source submission: 593c580f-61de-42af-90d6-2b76cd743e58 Evidence-honesty note: 20/30 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. 29/30 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This synthesis tests the thesis that evidence for Rapamycin Biomarker Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Rapamycin, an mTOR inhibitor, is increasingly investigated for potential geroprotective and biomarker-modulating effects, yet its clinical translation from preclinical models remains contested. This synthesis employed an AI-assisted structured evidence synthesis with an audit trail to integrate findings across 30 curated reference papers spanning preclinical, observational, and randomized controlled trial designs.